Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
Meanwhile, Akeso challenges Moderna and BioNTech with an mRNA neoantigen play.
The THIO-104 study listing is live, along with questions about funding the trial.
Golcadomide will begin a new pivotal trial in follicular lymphoma.
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
The company will soon start a pivotal trial of its IL-12 gene therapy, but cash is short.
The private US biotech features among recent first-in-human study entrants, with another PARP1-selective molecule.
